Recent Updates
Recently added Catalysts
CV Positive Sentiment Score: 75/100

CapsoVision to Release First Quarter 2026 Financial Results on May 14, 2026

Key Takeaway: CapsoVision, Inc. will announce its first quarter 2026 financial results on May 14, 2026. A conference call and webcast will follow the results release, allowing for investor engagement. The company focuses on advanced imaging and AI solutions for gastrointestinal diagnostics, with notable products in its pipeline.

Market Sentiment Analysis

POSITIVE FACTORS

  • CapsoVision is set to release its financial results, indicating ongoing business activity.
  • The company is developing innovative imaging and AI-enabled solutions for gastrointestinal diseases.
  • CapsoVision's products, like CapsoCam Plus, are enhancing diagnostic capabilities.

Full Press Release Details

SARATOGA, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that the Company will release first quarter 2026 financial results on Thursday, May 14, 2026, after the close of market. CapsoVision will host a corresponding conference call and a live webcast at 1:30 pm PT / 4:30 pm ET on the same day to discuss the results and provide a corporate update.
Investors interested in listening to the conference call may do so by dialing (800) 715-9871 or (646) 307-1963 and referencing conference ID 5439091. The live and archived webcast of the conference call can be found on theEventspage in the Investor Relations section of CapsoVision’s website.

About CapsoVision

CapsoVision is a commercial-stage medical technology company focused on developing advanced imaging and AI-enabled solutions to transform the detection and screening of gastrointestinal diseases. Its flagship product, CapsoCam Plus®, is a wire-free, panoramic capsule endoscope that enables high-resolution visualization of the small bowel and supports cloud-based or direct capsule video retrieval. The Company’s next pipeline product, CapsoCam Colon™ with enhanced AI, is designed to enable non-invasive colon imaging and polyp detection. With a proprietary platform targeted to expand across multiple GI indications, including esophageal and pancreatic disorders, CapsoVision is advancing a new era in capsule-based diagnostics. For more information on CapsoVision, please visitwww.capsovision.com.

Investor Relations ContactLeigh SalvoNew Street Investor RelationsInvestors@CapsoVision.com

Media ContactLeslie Strickler and Paul SpicerÊtre Communicationsleslies@etrecommunications.com| (804) 240-0807pauls@etrecommunications.com| (804) 503-9231

Frequently Asked Questions

When will CapsoVision release its Q1 2026 financial results?

CapsoVision will release its Q1 2026 financial results on May 14, 2026.

What time is the CapsoVision conference call?

The conference call will be held at 1:30 pm PT / 4:30 pm ET on May 14, 2026.

How can investors access the CapsoVision conference call?

Investors can access the call by dialing (800) 715-9871 or (646) 307-1963.

What is CapsoVision's flagship product?

CapsoVision's flagship product is the CapsoCam Plus®, a panoramic capsule endoscope.

What is the focus of CapsoVision's technology?

CapsoVision focuses on advanced imaging and AI-enabled solutions for gastrointestinal diseases.

Last updated: Apr 30, 2026